Market Summary
USD37.35-0.39
Market Closed-1.03%
BAX Stock Price
BAX RSI Chart
BAX Valuation
BAX Price/Sales (Trailing)
BAX Profitability
BAX Fundamentals
BAX Revenue
BAX Earnings
Price Action
52 Week Range
37.0557.52
(Low)(High)
Last 7 days
-0.4%
Last 30 days
-8%
Last 90 days
-16.4%
Trailing 12 Months
-29.8%
BAX Financial Health
BAX Investor Care
Historical Charts for Stock Metrics
Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
Get all data in R, Python etc through our Historical Stock Data APIs
Latest Insider Trading transactions for BAX
Filter Transactions| Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
|---|---|---|---|---|---|---|
2023-09-01 | Borzi James W | acquired | - | - | 12,016 | evp, chief supply chain office |
2023-09-01 | Sonig Alok | sold (taxes) | -83,595 | 40.6 | -2,059 | evp, group president, pharm |
2023-08-21 | RUSCKOWSKI STEPHEN H | acquired | - | - | 3,049 | - |
2023-06-29 | Ampofo William A. II | acquired | - | - | 3,811 | - |
2023-06-01 | Toth Christopher A. | acquired | - | - | 106,358 | evp, group pres, kidney care |
2023-06-01 | Rosenbloom David S. | sold (taxes) | -31,417 | 41.23 | -762 | svp and general counsel |
2023-06-01 | Stevens Brian | acquired | - | - | 5,909 | svp,interim cfo,cao&cntrl |
2023-05-02 | Smith Cathy R | acquired | - | - | 4,573 | - |
2023-05-02 | Wilkes David S. | acquired | - | - | 4,573 | - |
2023-05-02 | Oesterle Stephen N. | acquired | - | - | 4,573 | - |
Which funds bought or sold BAX recently?
View All Details| Datesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
|---|---|---|---|---|---|---|
2023-09-26 | BROOKFIELD Corp /ON/ | new | - | 6,192,290 | 6,192,290 | 0.02% |
2023-09-21 | Baystate Wealth Management LLC | reduced | -68.27 | -39,016 | 21,621 | -% |
2023-09-20 | BARCLAYS PLC | reduced | -10.6 | 157,000 | 38,366,000 | 0.02% |
2023-09-19 | BIRMINGHAM CAPITAL MANAGEMENT CO INC/AL | reduced | -0.93 | 73,916 | 728,960 | 0.30% |
2023-09-18 | WASHINGTON CAPITAL MANAGEMENT, INC | added | 19.88 | 397,069 | 1,542,890 | 1.31% |
2023-09-12 | Farther Finance Advisors, LLC | added | 28.52 | 16,593 | 53,989 | 0.01% |
2023-09-12 | DAVIDSON KEMPNER CAPITAL MANAGEMENT LP | sold off | -100 | -16,224,000 | - | -% |
2023-09-01 | Portside Wealth Group, LLC | new | - | 781,568 | 781,568 | 0.14% |
2023-08-29 | Garde Capital, Inc. | reduced | -5.36 | 7,000 | 108,000 | 0.01% |
2023-08-28 | DT Investment Partners, LLC | unchanged | - | -141 | 2,655 | -% |
Latest Funds Activity
Calls
Puts
Net Call Options
No. of Funds
Schedule 13G FIlings of Baxter International
| Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
|---|---|---|---|---|---|
| May 09, 2023 | morgan stanley | 0.6% | 3,186,104 | SC 13G/A | |
| Apr 10, 2023 | wellington management group llp | 0.11% | 559,390 | SC 13G/A | |
| Apr 10, 2023 | vanguard group inc | 12.03% | 60,794,820 | SC 13G/A | |
| Feb 09, 2023 | vanguard group inc | 9.86% | 49,705,350 | SC 13G/A | |
| Feb 08, 2023 | morgan stanley | 5.5% | 27,835,167 | SC 13G/A | |
| Feb 06, 2023 | wellington management group llp | 7.16% | 36,104,233 | SC 13G/A | |
| Jan 06, 2023 | blackrock inc. | 10.0% | 50,522,292 | SC 13G/A | |
| Mar 10, 2022 | wellington management group llp | 11.33% | 56,894,500 | SC 13G/A | |
| Feb 09, 2022 | morgan stanley | 5.7% | 28,501,661 | SC 13G | |
| Feb 09, 2022 | vanguard group inc | 7.79% | 38,980,284 | SC 13G/A |
Recent SEC filings of Baxter International
View All Filings| Date Filed | Form Type | Document | |
|---|---|---|---|
| Oct 02, 2023 | 8-K | Current Report | |
| Sep 06, 2023 | 4 | Insider Trading | |
| Sep 06, 2023 | 4 | Insider Trading | |
| Aug 23, 2023 | 4 | Insider Trading | |
| Aug 23, 2023 | 3 | Insider Trading | |
| Aug 21, 2023 | 8-K | Current Report | |
| Jul 27, 2023 | 8-K | Current Report | |
| Jul 27, 2023 | 10-Q | Quarterly Report | |
| Jul 06, 2023 | 8-K | Current Report | |
| Jul 03, 2023 | 4 | Insider Trading |
Peers (Alternatives to Baxter International)
View All Peers In Detail| Name | Mkt Capsorted ascending | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
|---|---|---|---|---|---|---|---|---|
| LARGE-CAP | ||||||||
SYK | 104.0B | 19.5B | -3.73% | 35.20% | 38.38 | 5.34 | 10.36% | 30.30% |
ISRG | 103.6B | 6.7B | -4.97% | 57.37% | 72.72 | 15.55 | 11.75% | -0.66% |
BSX | 76.4B | 13.4B | -1.51% | 36.35% | 83.74 | 5.7 | 8.69% | 3.17% |
BDX | 71.3B | 19.0B | -7.43% | 16.56% | 44.09 | 3.79 | 0.46% | -5.24% |
EW | 42.1B | 5.7B | -9.43% | -16.28% | 30.27 | 7.43 | 5.64% | -4.53% |
| MID-CAP | ||||||||
PEN | 9.1B | 937.8M | -9.65% | 25.86% | 313.94 | 9.75 | 16.30% | 250.21% |
SWAV | 7.2B | 616.6M | -11.74% | -29.40% | 29.51 | 11.67 | 69.52% | 343.68% |
GMED | 5.0B | 1.1B | -8.56% | -16.75% | 23.67 | 4.54 | 12.63% | 50.85% |
IRTC | 2.8B | 452.1M | -10.08% | -26.48% | -28.35 | 6.22 | 24.99% | 24.09% |
TNDM | 1.4B | 790.3M | -21.04% | -54.04% | -6.37 | 1.81 | 3.21% | -1604.53% |
| SMALL-CAP | ||||||||
ATEC | 1.5B | 421.8M | -22.58% | 43.94% | -9.18 | 3.63 | 44.49% | -2.43% |
AVNS | 945.1M | 780.7M | -5.83% | -7.35% | -26.25 | 1.21 | 4.68% | -510.17% |
CSII | 839.3M | 239.8M | 0.70% | 0.15% | -22.16 | 3.5 | -4.74% | -31.15% |
SILK | 589.9M | 162.9M | -22.80% | -66.22% | -11.16 | 3.62 | 42.67% | 12.82% |
Baxter International News
Returns for BAX
Cumulative Returns on BAX
2.1%
10-Year Cumulative Returns
-2.2%
7-Year Cumulative Returns
-12.1%
5-Year Cumulative Returns
-20.9%
3-Year Cumulative Returns
Risks for BAX
What is the probability of a big loss on BAX?
43.9%
Probability that Baxter International stock will be more than 20% underwater in next one year
24.2%
Probability that Baxter International stock will be more than 30% underwater in next one year.
14.2%
Probability that Baxter International stock will be more than 40% underwater in next one year.
*Calculated based on probability distribution of losses observed in actual data in the last 5 years.
How does BAX drawdown profile look like?
Y-axis is the maximum loss one would have experienced if Baxter International was unfortunately bought at previous high price.
Drawdowns
Financials for Baxter International
Income Statement (Last 12 Months)(In Millions)
| Income Statement (Last 12 Months) | (In Millions) | |||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Description | (%) Q/Q | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 | 2018Q4 | 2018Q3 | 2018Q2 |
| Revenue | 0.8% | 15,016 | 14,903 | 15,113 | 14,588 | 14,041 | 13,545 | 12,784 | 12,451 | 12,197 | 11,817 | 11,673 | 11,531 | 11,410 | 11,526 | 11,362 | 11,156 | 11,066 | 11,045 | 11,099 | 11,040 | 10,986 |
| Gross Profit | -4.9% | 5,054 | 5,314 | 5,397 | 5,258 | 5,446 | 5,308 | 5,105 | 4,890 | 4,764 | 4,569 | 4,587 | 4,694 | 4,729 | 4,844 | 4,761 | 4,646 | 4,648 | 4,718 | 4,759 | 4,740 | 4,638 |
| S&GA Expenses | -0.2% | 3,833 | 3,839 | 3,887 | 3,854 | 3,587 | 3,292 | 2,867 | 2,632 | 2,553 | 2,468 | 2,469 | 2,485 | 2,511 | 2,562 | 2,535 | 2,496 | 2,553 | 2,588 | 2,620 | 2,746 | 2,742 |
| R&D Expenses | 2.7% | 636 | 619 | 605 | 588 | 565 | 556 | 534 | 531 | 525 | 503 | 521 | 542 | 563 | 612 | 595 | 614 | 636 | 642 | 654 | 662 | 646 |
| EBITDA | 100.0% | - | -1,462 | -1,345 | -1,332 | 2,011 | 2,030 | 2,175 | 2,106 | 2,084 | 1,959 | 1,981 | 1,562 | 1,640 | 1,684 | 1,688 | 2,301 | - | - | - | - | - |
| EBITDA Margin | 100.0% | - | -0.10* | -0.09* | -0.09* | 0.14* | 0.15* | 0.17* | 0.17* | 0.17* | 0.17* | 0.17* | 0.14* | 0.14* | 0.15* | 0.15* | 0.21* | - | - | - | - | - |
| Interest Expenses | -8.2% | -462 | -427 | -395 | -352 | -298 | -243 | -192 | -156 | -145 | -147 | -134 | -116 | -90.00 | -74.00 | -71.00 | -62.00 | -60.00 | -51.00 | -45.00 | -48.00 | -51.00 |
| Earnings Before Taxes | -16.4% | -2,855 | -2,453 | -2,353 | -2,370 | 1,047 | 1,220 | 1,477 | 1,404 | 1,368 | 1,265 | 1,292 | 859 | 925 | 962 | 970 | 1,606 | 1,497 | 1,575 | 1,617 | 1,380 | 1,298 |
| EBT Margin | 100.0% | - | -0.16* | -0.16* | -0.16* | 0.08* | 0.09* | 0.12* | 0.11* | 0.11* | 0.11* | 0.11* | 0.07* | 0.08* | 0.08* | 0.09* | 0.14* | - | - | - | - | - |
| Net Income | -16.0% | -2,853 | -2,460 | -2,433 | -2,376 | 1,011 | 1,057 | 1,284 | 1,214 | 1,120 | 1,068 | 1,102 | 911 | 924 | 991 | 1,001 | 1,329 | 1,478 | 1,506 | 1,546 | 1,170 | 903 |
| Net Income Margin | 100.0% | - | -0.16* | -0.16* | -0.16* | 0.07* | 0.08* | 0.10* | 0.10* | 0.09* | 0.09* | 0.09* | 0.08* | 0.08* | 0.09* | 0.09* | 0.12* | - | - | - | - | - |
| Free Cashflow | -100.0% | - | 1,482 | 1,211 | 1,465 | 1,850 | 2,053 | 2,222 | 2,241 | 2,076 | 1,973 | 1,868 | 1,985 | 2,176 | 2,234 | 2,104 | 2,030 | - | - | - | - | - |
Balance Sheet(In Millions)
| Balance Sheet | (In Millions) | |||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Description | (%) Q/Q | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 | 2018Q4 | 2018Q3 | 2018Q2 |
| Assets | -1.4% | 27,885 | 28,291 | 28,287 | 27,965 | 31,831 | 32,716 | 33,521 | 19,807 | 19,682 | 19,466 | 20,019 | 20,098 | 19,465 | 19,075 | 18,193 | 17,299 | 17,503 | 16,241 | 15,720 | 16,803 | 16,519 |
| Current Assets | 1.3% | 8,205 | 8,099 | 8,011 | 7,810 | 7,882 | 8,173 | 8,872 | 8,167 | 8,004 | 7,856 | 8,411 | 9,033 | 8,566 | 8,333 | 7,503 | 7,210 | 7,229 | 6,060 | 5,959 | 7,031 | 6,884 |
| Cash Equivalents | 2.8% | 1,720 | 1,673 | 1,718 | 1,601 | 1,852 | 2,294 | 2,956 | 3,258 | 3,136 | 3,182 | 3,730 | 4,359 | 4,085 | 4,110 | 3,335 | 3,000 | 2,934 | 1,902 | 1,838 | 2,863 | 2,858 |
| Inventory | -0.9% | 2,897 | 2,922 | 2,679 | 2,675 | 2,663 | 2,548 | 2,453 | 2,025 | 2,065 | 2,017 | 1,916 | 1,988 | 1,905 | 1,694 | 1,653 | 1,715 | 1,756 | 1,743 | 1,667 | 1,716 | 1,616 |
| Net PPE | -10.1% | 4,494 | 5,000 | 4,695 | 4,799 | 4,976 | 5,114 | 5,178 | 4,582 | 4,649 | 4,614 | 4,722 | 4,460 | 4,382 | 4,340 | 4,512 | 4,406 | 4,485 | 4,476 | 4,530 | 4,476 | 4,486 |
| Goodwill | -6.6% | 6,418 | 6,868 | 6,452 | 6,639 | 9,644 | 9,816 | 9,836 | 3,098 | 3,148 | 1.00 | 3,217 | 3,094 | 3,052 | 2,961 | 3,030 | 2,847 | 2,937 | 2,929 | 3,002 | - | - |
| Liabilities | -0.4% | 22,254 | 22,350 | 22,392 | 22,386 | 22,928 | 23,597 | 24,400 | 10,992 | 11,147 | 10,976 | 11,293 | 11,496 | 11,305 | 11,345 | 10,281 | 9,682 | 9,700 | 8,648 | 7,854 | 7,713 | 7,689 |
| Current Liabilities | 21.1% | 5,765 | 4,760 | 4,745 | 3,708 | 3,916 | 3,890 | 4,236 | 3,441 | 3,344 | 3,187 | 3,333 | 3,422 | 2,880 | 3,036 | 3,230 | 2,611 | 2,557 | 3,276 | 2,814 | 2,663 | 2,586 |
| Short Term Borrowings | 398.0% | 249 | 50.00 | 299 | 275 | 200 | 200 | 301 | 301 | 51.00 | - | - | - | 1.00 | 221 | 226 | - | 2.00 | 796 | 2.00 | - | - |
| Long Term Debt | -6.4% | 14,306 | 15,278 | 15,232 | 16,153 | - | - | 17,149 | - | - | - | - | - | - | - | 4,809 | - | 5,157 | 3,451 | 3,481 | 3,480 | 3,491 |
| Shareholder's Equity | -6.3% | 5,569 | 5,941 | 5,833 | 5,535 | 8,903 | 9,119 | 9,121 | 8,815 | 8,535 | 8,490 | 8,726 | 8,602 | 8,160 | 7,730 | 7,912 | 7,617 | 7,803 | 7,593 | 7,866 | 9,090 | 8,830 |
| Retained Earnings | -2.1% | 13,655 | 13,947 | 14,050 | 14,015 | 17,099 | 16,994 | 17,065 | 16,967 | 16,658 | 16,502 | 16,328 | 16,285 | 16,055 | 15,935 | 15,718 | 15,849 | 15,598 | 15,414 | 15,075 | 14,886 | 14,484 |
| Additional Paid-In Capital | 0.5% | 6,341 | 6,312 | 6,322 | 6,297 | 6,253 | 6,207 | 6,197 | 6,131 | 6,090 | 6,043 | 6,043 | 6,009 | 5,975 | 5,935 | 5,955 | 5,926 | 5,906 | 5,839 | 5,898 | 5,931 | 5,916 |
| Shares Outstanding | 0.2% | 506 | 505 | - | 504 | 504 | 503 | - | 500 | 503 | 505 | - | 511 | 509 | 507 | - | 511 | 510 | 512 | - | 534 | 535 |
| Minority Interest | 0% | 62.00 | 62.00 | 62.00 | 44.00 | 44.00 | 44.00 | 44.00 | 45.00 | 41.00 | 38.00 | 37.00 | 35.00 | 32.00 | 31.00 | 30.00 | 29.00 | 24.00 | 23.00 | 22.00 | -17.00 | -12.00 |
Cashflow (Last 12 Months)(In Millions)
| Cashflow (Last 12 Months) | (In Millions) | |||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Description | (%) Q/Q | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 | 2018Q4 | 2018Q3 | 2018Q2 |
| Cashflow From Operations | 5.2% | 1,559 | 1,482 | 1,211 | 1,465 | 1,850 | 2,053 | 2,222 | 2,241 | 2,076 | 1,973 | 1,868 | 1,985 | 2,176 | 2,248 | 2,104 | 1,984 | 1,759 | 1,715 | 2,017 | 1,699 | 1,828 |
| Share Based Compensation | -5.4% | 139 | 147 | 154 | 175 | 164 | 156 | 146 | 126 | 125 | 123 | 130 | 127 | 129 | 129 | 122 | 120 | 118 | 117 | 115 | 117 | 115 |
| Cashflow From Investing | 1.8% | -783 | -797 | -931 | -10,942 | -10,965 | -10,966 | -11,200 | -1,197 | -1,147 | -1,113 | -1,179 | -1,336 | -1,410 | -1,403 | -1,100 | -895 | -833 | -846 | -916 | -904 | -1,510 |
| Cashflow From Financing | 27.7% | -913 | -1,262 | -1,438 | 7,957 | 7,935 | 8,055 | 8,245 | -2,174 | -1,961 | -1,873 | -345 | 682 | 439 | 1,430 | 498 | -894 | -827 | -1,820 | -2,603 | -1,393 | -1,281 |
| Dividend Payments | 0.9% | 584 | 579 | 573 | 567 | 562 | 545 | 530 | 515 | 499 | 487 | 473 | 461 | 448 | 433 | 423 | 412 | 401 | 390 | 376 | 361 | 347 |
| Buy Backs | - | - | - | 32.00 | 32.00 | 35.00 | 347 | 600 | 1,100 | 1,065 | 753 | 500 | 241 | 550 | 673 | 1,270 | 2,453 | 2,391 | 2,527 | 2,452 | 1,317 | 1,250 |
BAX Income Statement
2023-06-30Condensed Consolidated Statements of Income (Loss) (unaudited) - USD ($) shares in Millions, $ in Millions | 3 Months Ended | 6 Months Ended | ||
|---|---|---|---|---|
Jun. 30, 2023 | Jun. 30, 2022 | Jun. 30, 2023 | Jun. 30, 2022 | |
| Income Statement [Abstract] | ||||
| Net sales | $ 3,707 | $ 3,594 | $ 7,220 | $ 7,152 |
| Cost of sales | 2,596 | 2,223 | 4,834 | 4,519 |
| Gross margin | 1,111 | 1,371 | 2,386 | 2,633 |
| Selling, general and administrative expenses | 964 | 970 | 1,959 | 2,017 |
| Research and development expenses | 165 | 148 | 329 | 297 |
| Other operating income, net | (1) | (11) | (14) | (28) |
| Operating income (loss) | (17) | 264 | 112 | 347 |
| Interest expense, net | 124 | 89 | 241 | 174 |
| Other (income) expense, net | 42 | (44) | 40 | (60) |
| Income (loss) from continuing operations before income taxes | (183) | 219 | (169) | 233 |
| Income tax expense | 10 | 34 | 24 | 40 |
| Income (loss) from continuing operations | (193) | 185 | (193) | 193 |
| Income from discontinued operations, net of tax | 54 | 70 | 99 | 135 |
| Net income (loss) | (139) | 255 | (94) | 328 |
| Net income attributable to noncontrolling interests | 2 | 3 | 3 | 5 |
| Net income (loss) attributable to Baxter stockholders | $ (141) | $ 252 | $ (97) | $ 323 |
| Income (loss) from continuing operations per common share | ||||
| Income from continuing operations per common share, basic (in dollars per share) | $ (0.39) | $ 0.36 | $ (0.39) | $ 0.37 |
| Income from continuing operations per common share, diluted (in dollars per share) | (0.39) | 0.36 | (0.39) | 0.37 |
| Income from discontinued operations per common share | ||||
| Income from discontinued operations per common share, basic (in dollars per share) | 0.11 | 0.14 | 0.20 | 0.27 |
| Income from discontinued operations per common share, diluted (in dollars per share) | 0.11 | 0.14 | 0.20 | 0.27 |
| Net income (loss) per common share | ||||
| Basic (in dollars per share) | (0.28) | 0.50 | (0.19) | 0.64 |
| Diluted (in dollars per share) | $ (0.28) | $ 0.50 | $ (0.19) | $ 0.64 |
| Weighted-average number of shares outstanding | ||||
| Basic (in shares) | 506 | 504 | 506 | 503 |
| Diluted (in shares) | 506 | 508 | 506 | 508 |
BAX Balance Sheet
2023-06-30Condensed Consolidated Balance Sheets (unaudited) - USD ($) $ in Millions | Jun. 30, 2023 | Dec. 31, 2022 |
|---|---|---|
| Current assets: | ||
| Cash and cash equivalents | $ 1,722 | $ 1,718 |
| Accounts receivable, net of allowances of $128 in 2023 and $114 in 2022 | 2,495 | 2,571 |
| Inventories | 2,897 | 2,679 |
| Prepaid expenses and other current assets | 858 | 857 |
| Current assets of discontinued operations | 233 | 186 |
| Total current assets | 8,205 | 8,011 |
| Property, plant and equipment, net | 4,494 | 4,695 |
| Goodwill | 6,418 | 6,452 |
| Other intangible assets, net | 6,470 | 6,793 |
| Operating lease right-of-use assets | 533 | 541 |
| Other non-current assets | 1,067 | 1,109 |
| Non-current assets of discontinued operations | 698 | 686 |
| Total assets | 27,885 | 28,287 |
| Current liabilities: | ||
| Short-term debt | 249 | 299 |
| Current maturities of long-term debt and finance lease obligations | 1,928 | 1,105 |
| Accounts payable | 1,240 | 1,110 |
| Accrued expenses and other current liabilities | 2,278 | 2,170 |
| Current liabilities of discontinued operations | 70 | 61 |
| Total current liabilities | 5,765 | 4,745 |
| Long-term debt and finance lease obligations, less current portion | 14,306 | 15,232 |
| Operating lease liabilities | 438 | 447 |
| Other non-current liabilities | 1,622 | 1,848 |
| Non-current liabilities of discontinued operations | 123 | 120 |
| Total liabilities | 22,254 | 22,392 |
| Commitments and contingencies | ||
| Equity: | ||
| Common stock, $1 par value, authorized 2,000,000,000 shares, issued 683,494,944 shares in 2023 and 2022 | 683 | 683 |
| Common stock in treasury, at cost, 177,125,182 shares in 2023 and 179,062,594 shares in 2022 | (11,296) | (11,389) |
| Additional contributed capital | 6,341 | 6,322 |
| Retained earnings | 13,655 | 14,050 |
| Accumulated other comprehensive income (loss) | (3,814) | (3,833) |
| Total Baxter stockholders’ equity | 5,569 | 5,833 |
| Noncontrolling interests | 62 | 62 |
| Total equity | 5,631 | 5,895 |
| Total liabilities and equity | $ 27,885 | $ 28,287 |
Baxter International Inc., through its subsidiaries, develops and provides a portfolio of healthcare products worldwide. The company offers peritoneal dialysis and hemodialysis, and additional dialysis therapies and services; intravenous therapies, infusion pumps, administration sets, and drug reconstitution devices; remixed and oncology drug platforms, inhaled anesthesia and critical care products and pharmacy compounding services; parenteral nutrition therapies and related products; biological products and medical devices used in surgical procedures for hemostasis, tissue sealing and adhesion prevention; and continuous renal replacement therapies and other organ support therapies focused in the intensive care unit. It also provides connected care solutions, including devices, software, communications, and integration technologies; integrated patient monitoring and diagnostic technologies to help diagnose, treat, and manage a various illness and diseases, including respiratory therapy, cardiology, vision screening, and physical assessment; surgical video technologies, tables, lights, pendants, precision positioning devices and other accessories. In addition, the company offers contracted services to various pharmaceutical and biopharmaceutical companies. Its products are used in hospitals, kidney dialysis centers, nursing homes, rehabilitation centers, doctors' offices, and patients at home under physician supervision. The company sells its products through direct sales force, as well as through independent distributors, drug wholesalers, and specialty pharmacy or other alternate site providers in approximately 100 countries. It has an agreement with Celerity Pharmaceutical, LLC to develop acute care generic injectable premix and oncolytic molecules. Baxter International Inc. was incorporated in 1931 and is headquartered in Deerfield, Illinois.